Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
2상
진행 중(모집 완료)
NCT02883062
| 대상 질환 | Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | National Cancer Institute (NCI) |
|---|
| 상태 | 진행 중(모집 완료) |
|---|
| 참여자 수 | 67 명 |
|---|
| 중재(약물) | Atezolizumab, Biospecimen Collection, Carboplatin, Lumpectomy, Mastectomy |
|---|
| 시작일 | 2017년 8월 2일 |
|---|
| 완료일 | 2019년 12월 18일 |
|---|
| 결과 공개일 | 2024년 6월 18일 |
|---|
요약
This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carboplatin and paclitaxel with or without atezolizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Change in Tumor Infiltrating Lymphocyte (TIL) Percentage
Baseline and between days 18-22 following completion of cycle 1 (each cycle is 3 weeks) · percentage of TIL
| Arm A (Carboplatin, Paclitaxel, Mastectomy, Lumpectomy) | 16.7 percentage of TIL |
|---|
| Arm B (Atezolizumab, Carboplatin, Paclitaxel, Breast Surgery) | 17.5 percentage of TIL |
|---|
| Arm A (Carboplatin, Paclitaxel, Mastectomy, Lumpectomy) | 18.3 percentage of TIL |
|---|
| Arm B (Atezolizumab, Carboplatin, Paclitaxel, Breast Surgery) | 21.7 percentage of TIL |
|---|
Pathologic Complete Response (pCR) Rate
At the time of surgery (3-6 weeks after last dose of neoadjuvant chemotherapy, neoadjuvant chemotherapy will be up to 12 weeks in length) · Participants
| Arm A (Carboplatin, Paclitaxel, Mastectomy, Lumpectomy) | 3 Participants |
|---|
| Arm B (Atezolizumab, Carboplatin, Paclitaxel, Breast Surgery) | 25 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.